Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides by Steinert, Robert E. et al.
Effects of carbohydrate sugars and artificial sweeteners on appetite
and the secretion of gastrointestinal satiety peptides
Robert E. Steinert*, Florian Frey, Antonia To¨pfer, Ju¨rgen Drewe and Christoph Beglinger
Division of Gastroenterology, Department of Biomedicine, Clinical Research Center, University Hospital Basel, CH-4031
Basel, Switzerland
(Received 25 May 2010 – Revised 9 November 2010 – Accepted 10 November 2010 – First published online 24 January 2011)
Abstract
In vitro, both carbohydrate sugars and artificial sweeteners (AS) stimulate the secretion of glucagon-like peptide-1 (GLP-1). It has been
suggested that the gut tastes sugars and AS through the same mechanisms as the tongue, with potential effects on gut hormone release.
We investigated whether the human gut responds in the same way to AS and carbohydrate sugars, which are perceived by lingual taste as
equisweet. We focused on the secretion of gastrointestinal (GI) satiety peptides in relation to appetite perception. We performed a placebo-
controlled, double-blind, six-way, cross-over trial including twelve healthy subjects. On separate days, each subject received an intragastric
infusion of glucose, fructose or an AS (aspartame, acesulfame K and sucralose) dissolved in 250 ml of water or water only (control). In a
second part, four subjects received an intragastric infusion of the non-sweet, non-metabolisable sugar analogue 2-deoxy-D-glucose. Glu-
cose stimulated GLP-1 (P¼0·002) and peptide tyrosine tyrosine (PYY; P¼0·046) secretion and reduced fasting plasma ghrelin (P¼0·046),
whereas fructose was less effective. Both carbohydrate sugars increased satiety and fullness (albeit not significantly) compared with water.
In contrast, equisweet loads of AS did not affect gastrointestinal peptide secretion with minimal effects on appetite. 2-Deoxy-D-glucose
increased hunger ratings, however, with no effects on GLP-1, PYY or ghrelin. Our data demonstrate that the secretion of GLP-1, PYY
and ghrelin depends on more than the detection of (1) sweetness or (2) the structural analogy to glucose.
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There is strong evidence that taste-signalling mechanisms
identified in the oral epithelium also operate in the gut. It
has been suggested that open-type enteroendocrine cells
directly sense nutrients via G-protein-coupled receptors to
modulate the secretion of gastrointestinal (GI) peptides(1–5).
One example supporting this idea is that a much greater insu-
lin response occurs after an oral glucose load, i.e. after direct
contact of glucose with the intestinal lumen, than after
intravenous injection of an identical glucose load(6). The so-
called ‘incretin effect’ is attributed to glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide
(GIP); both are released from enteroendocrine K and L cells
in the proximal and distal gut. In addition to this incretin
effect, GLP-1 and other GI peptides including cholecystokinin
and peptide tyrosine tyrosine (PYY) delay gastric emptying
and dose-dependently reduce food intake in animals and
humans(7–9). For GLP-1, long-acting analogues are already
clinically available (exenatide and liraglutide) for the treat-
ment of type 2 diabetes mellitus. In some of these studies, it
has been shown that subcutaneous injections of exenatide, a
stable GLP-1 receptor agonist, to patients with type 2 diabetes
are associated with a gradual and linear weight loss with no
signs of impaired efficacy with time(10). The question, there-
fore, is whether it is possible to increase the secretion of
these peptides from endogenous stores using specific stimuli.
In this regard, Jang et al.(2) demonstrated that glucose-
stimulated GLP-1 and GIP secretion is impaired in knockout
mice lacking a-gustducin (a taste-specific G-protein subunit)
or T1R3 (part of the sweet-taste receptor heterodimer T1R2/
T1R3)(2). In addition, in vitro, both carbohydrate sugars and
artificial sweeteners (AS) were capable of stimulating GLP-1
and GIP release from enteroendocrine cell lines (GLUTag,
NCI-H716)(2,4). It is, therefore, currently concluded that the
gut directly senses glucose or other sweet compounds by
sweet-taste G-protein-coupled receptors and gustducin and
that this leads to GLP-1 release from enteroendocrine
cells(11). We, therefore, sought to investigate whether
carbohydrate sugars and AS (aspartame, acesulfame K and
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sucralose), which are perceived by lingual taste as equisweet,
have equivalent effects on the release of GI peptides and
appetite perception in human subjects.
Subjects and methods
Subjects
The study included twelve healthy, non-smoking, volunteers
(six males and six females, mean age 23·3 (SEM 0·7; range
19–29) years). Body weight of all subjects was in the
normal range for age, sex and height and stable for at least
3 months (mean BMI 23·0 (SEM 0·5; range 20·5–24·7) kg/m2).
The criteria for exclusion were smoking, substance abuse,
chronic medical or psychiatric illness, and any abnormalities
detected on physical examination or screening blood tests.
None of the subjects had a history of food allergies or dietary
restrictions. The study was conducted according to the
guidelines laid down in the Declaration of Helsinki, and all
procedures involving human subjects were approved by the
State Ethical Committee of Basel. Written informed consent
was obtained from all subjects.
Study design
Administration of artificial sweeteners or carbohydrate sugars.
The study was performed as a randomised, placebo-
controlled, double-blind, six-way cross-over trial. The six
treatments were separated by at least 3–5 d. Subjects were
instructed to abstain from alcohol, caffeine and strenuous
exercise for 24 h before each treatment. On each test day, sub-
jects reported to the research unit at 08.00 hours after a 10 h
overnight fast. After arrival at the research unit, a radio-
opaque polyvinyl feeding tube (external diameter 8 French)
was inserted into the stomach through an anaesthetised nos-
tril. Its intragastric position was confirmed by rapid injection
of 10 ml of air and auscultation of the upper abdomen. The
feeding tube was firmly attached to the skin behind the ear
to prevent further progression during the treatment. An intra-
venous cannula was inserted into a forearm vein for blood
sample collection. A baseline blood sample was taken,
before each subject received an intragastric infusion of
250 ml of the test solution over 2 min (t ¼ 0–2 min). Solutions
were equated for sweetness intensity with each other in
preliminary psychophysical tests. Healthy volunteers rated
the sweetness of different test solutions and equated them
with a standard 50 g of glucose solution (positive control).
The results largely confirmed previous estimates by Rogers
et al.(12) and Bellisle & Drewnowski(13), and the concentrations
were comparable with the amounts found in commercially
available beverages and soft drinks (Table 1).
The control solution was 250 ml of tap water only. Solutions
were freshly prepared each morning of the study and were at
room temperature when administered. The feeding tube was
removed directly after the infusion was completed, and
blood was drawn at regular time intervals at 5, 10, 15, 20,
30, 45, 60, 75, 90 and 120 min. Blood samples were collected
on ice into tubes containing EDTA (6mmol/l), aprotinin
(500 kIU/l; 0·07 mg aprotinin/ml blood) and a dipeptidyl pep-
tidase IV inhibitor. After centrifugation at 48C, plasma samples
were processed into different aliquots and kept frozen at
2708C until analysis. The appetite profile (hunger, satiety
and fullness) was assessed using visual analogue scales,
100 mm (or 10 cm) in length with words anchored at each
end, expressing the most positive and most negative
rating(14,15). For example, a score of 0 for hunger indicated
that the subject was not hungry at all, 2 indicated slightly
hungry, 5 indicated moderately hungry, 8 indicated very
hungry and 10 indicated absolutely ravenous. Subjects had
no exposure to food cues during evaluation, and they were
allowed to talk, relax and read with the exception that they
could not discuss or compare their ratings. Vital signs (blood
pressure and heart rate) were continuously measured while
subjects were sitting in a comfortable armchair.
Administration of 2-deoxy-D-glucose. In an additional
experiment, four subjects (two males and two females)
received an intragastric infusion of 2-deoxy-D-glucose
(2DG), a non-sweet, non-metabolisable structural analogue
of glucose. In total, 3·75 g of 2DG were dissolved in 250 ml
of tap water; the same experimental set-up was used, and
the effects on GI peptide secretion, appetite and glucose
homeostasis were compared with the data of the first exper-
iment. Blood samples were collected before and 30, 60 and
120 min after intragastric infusion. The appetite profile was
assessed using visual analogue scales, and vital signs were
continuously measured.
Laboratory analysis
Active GLP-1 was measured, as has been described
recently(16), using a commercially available ELISA kit (Linco
Research, Inc., St Charles, MO, USA). This kit is for non-
radioactive quantification of biologically active forms of
Table 1. Nutritional composition/sweetening power of the test solutions
Sweetness intensity v. sucrose Amount of sweetener (mg) Energy content (kJ) CHO (g) Fat (g) Protein (g)
Aspartame* 100–200 169 ,5 0 0 0
Acesulfame K* 100–200 220 0 0 0 0
Sucralose* 600 62 0 0 0 0
Fructose* 1·5 25 000 428·5 25 0 0
Glucose* 0·75 50 000 856·9 50 0 0
Water 0 0 0 0 0 0
CHO, carbohydrates.
* Amount of each sweetener was dissolved in 250 ml of tap water.
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GLP-1 (i.e. 7–36 amide and 7–37) in the plasma and other
biological media. Total PYY, total ghrelin, insulin and gluca-
gon were measured with commercially available RIA kits
(Linco Research, Inc.; Cisbio International, Bagnols, France;
Siemens Medical Solution Diagnostics, Los Angeles, CA,
USA); the methods have been described recently in more
detail(16). Blood glucose was measured using the glucose
oxidase method.
Materials
Glucose monohydrate and fructose were purchased at Ha¨nse-
ler (Herisau, Switzerland); aspartame was purchased at Fagron
(Barsbuettel, Germany); sucralose and 2DG were purchased at
Sigma-Aldrich (Buchs, Switzerland). Acesulfame K was a
friendly gift of Merisant Company (Neuchatel, Switzerland).
Statistical analysis
Descriptive statistics was used for demographic variables such
as age, weight, height and BMI. Individual hormone
concentrations v. time data were used to obtain GLP-1, PYY
and ghrelin metrics, including maximum/minimum plasma
concentrations (Cmax/Cmin), the time of maximal/minimal pep-
tide occurrence (Tmax/Tmin) and the area under the plasma
concentration–time curve (AUC) calculated by the trapezoidal
method. Differences between water and either carbohydrate
sugars or AS were assessed using the non-parametric Fried-
man test due to non-normal data distribution. In the case of
significant differences, pairwise comparison was performed
using the Wilcoxon signed-rank test, followed by Bonferroni’s
correction to account for multiple comparisons. Visual ana-
logue scales were analysed by calculating return to baseline
values (interception with the y-axis) using linear interpolation;
differences between water v. single treatment groups were
assessed using the non-parametric Friedman test due to dis-
tinct data variation and non-normal distribution. All statistical
analyses were done using SPSS for Windows software (version
15.0; SPSS, Chicago, IL, USA). Differences were considered to
be significant with P,0·05. Data are presented as means with
their standard errors.
Results
Administration of artificial sweeteners or carbohydrate
sugars
Plasma glucagon-like peptide-1. A marked increase in
plasma GLP-1 was seen after the glucose load, with
Cmax ¼ 9·7 (SEM 3·2) pmol/l at 22·9 (SEM 2·7) min. The AUC
was significantly increased (P¼0·002) compared with water.
The equisweet load of fructose only slightly elevated plasma
GLP-1 concentrations, with Cmax ¼ 2·8 (SEM 0·5) pmol/l at
20·8 (SEM 4·1) min; however, the AUC was not significantly
increased compared to water. No increase in plasma GLP-1
concentrations was seen after the administration of sucralose,
aspartame or acesulfame K, and no significant difference was
observed compared with water (Fig. 1(a) and Table 2).
Plasma peptide tyrosine tyrosine. A similar trend was
observed for plasma PYY concentrations with elevated con-
centrations after glucose (Cmax ¼ 187·4 (SEM 32·9) pg/l at 27·9
(SEM 3·7) min; P¼0·005) and to a lesser extent after fructose
administration (Cmax ¼ 154·8 (SEM 13·0) pg/l at 37·9 (SEM
6·6) min; P¼0·004). The AUC was, however, only significantly
increased after the glucose load (P¼0·046). No effect was
observed with fructose and AS (Fig. 1(b) and Table 2).
Plasma ghrelin. After the glucose and fructose load, fasting
plasma ghrelin concentrations were reduced; a significant
reduction in the AUC was only observed for glucose
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Fig. 1. (a) Glucagon-like peptide-1 (GLP-1), (b) peptide tyrosine tyrosine
(PYY) and (c) ghrelin release in response to an intragastric load of water
(–X–) or carbohydrate sugars (glucose (–W–) and fructose (–e–)) or
artificial sweeteners (aspartame (· · ·S· · ·), sucralose (· · ·A· · ·) or acesulfame
K (· · ·f· · ·)). Values are means, with their standard errors represented by
error bars.
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(P¼0·046). In contrast, sucralose, aspartame or acesulfame K
did not affect plasma ghrelin concentrations (Fig. 1(c) and
Table 2).
Blood glucose. After the intragastric infusion of glucose,
blood glucose concentrations were significantly increased
from 5·0 (SEM 0·1) mmol/l at baseline to 8·6 (SEM 0·4) mmol/l at
30·0 (SEM 4·6) min (P¼0·002) compared to water (Fig. 2(a)).
Thereafter, blood glucose concentrations decreased progress-
ively and fell below baseline at 90 min. With fructose adminis-
tration, blood glucose concentrations were slightly elevated to
5·7 (SEM 0·2) mmol/l at 24·2 (SEM 4·2) min (P¼0·047) (Fig. 2(a)).
The AS did not affect blood glucose concentrations.
Plasma insulin. Plasma insulin after glucose (Cmax ¼ 127·4
(SEM 19·2)mU/ml; P¼0·002) and fructose (Cmax ¼ 32·3 (SEM
2·0)mU/ml; P¼0·002) administration significantly increased
compared with water (Fig. 2(b)). No significant insulin
response was observed when sucralose, aspartame or acesul-
fame K was administered.
Plasma glucagon. Glucagon secretion was slightly sup-
pressed when glucose was administered; the effect was
albeit not significant. No effect on plasma glucagon was
detected with fructose and AS (data not shown).
Appetite profile. The appetite profile revealed that the
(energy-containing) carbohydrate sugar loads induced the
longest-lasting increase in fullness ratings above baseline,
which was prolonged for fructose 108·4 (SEM 6·1) min and
for glucose 90·5 (SEM 11·2) min. In contrast, water (74·0 (SEM
13·4) min) and the AS acesulfame K (65·6 (SEM 15·8) min),
aspartame (83·1 (SEM 15·9) min) and sucralose (65·3 (SEM
14·1) min) induced shorter augmented fullness above initial
ratings. However, due to the large data variability, these differ-
ences did not reach statistical significance (Fig. 3(c) and
Table 3). Satiety and hunger ratings showed similar trends,
however, with generally smaller differences. Overall, the AS
increased satiety and fullness and reduced hunger ratings to
an amount that was intermediate between the carbohydrate
sugars and the water control.
Side effects. No side effects were reported when glucose,
fructose or the AS was administered.
Administration of 2-deoxy-D-glucose
Plasma glucagon-like peptide-1, peptide tyrosine tyrosine and
ghrelin. Administration of 2DG did not stimulate the
secretion of GLP-1 and PYY; also circulating ghrelin was not
affected (data not shown).
Plasma glucose, glucagon and insulin. 2DG administration
markedly increased blood glucose from baseline concen-
trations of (5·5 (SEM 0·2) mmol/l) to peak concentrations of
11·2 (SEM 1·3) mmol/l at 120 min. Minor effects were observed
for plasma insulin with a small increase at 120 min. Plasma
glucagon appeared to slightly increase at 60 min compared
with water and glucose loads (Fig. 4(a)–(c)). Due to the
small number of subjects, no formal statistical comparison
was performed.
Appetite profile. After administration of 2DG, hunger rat-
ings were clearly increased compared to water, in contrast,
glucose visibly reduced hunger ratings from 30 to 120 min.T
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Feelings of fullness and satiety showed similar trends, with
glucose triggering increased fullness and satiety, whereas
2DG clearly reduced fullness and satiety ratings compared to
water (Fig. 4(d)–(f)). Due to the small number of subjects,
no formal statistical comparison was performed.
Side effects. No nausea or abdominal discomfort was
reported when 2DG was administered; also blood pressure
and heart rate were not significantly affected. However,
between 30 and 120 min, all subjects reported distinct feelings
of warmth and mild dizziness; two subjects sweated visibly.
Discussion
GLP-1 and PYY have important metabolic functions; both
have been shown to reduce food intake in humans(17).
GLP-1 also directly stimulates pancreatic b-cells; the so-called
incretin effect accounts for approximately 50–70 % of the total
insulin secretion after a meal(18). In addition, obese subjects
have attenuated plasma concentrations of both peptides,
suggesting major changes in regulatory functions(19,20). For
GLP-1, long-acting analogues are already clinically available
(exenatide and liraglutide) for the treatment of type 2
diabetes and, interestingly, subcutaneous injections of exena-
tide to patients with type 2 diabetes are associated with a
gradual and linear weight loss with no signs of impaired
efficacy with time. In view of this great therapeutic success,
the focus is now shifted towards intestinal endocrine cells
that naturally produce GLP-1 and PYY. The question is
whether it is possible to increase the secretion of these pep-
tides from endogenous stores using specific stimuli. However,
mechanisms by which carbohydrates, fats and proteins in the
gut lumen stimulate the release of GI peptides from enteroen-
docrine cells are only insufficiently understood. Regarding the
detection of carbohydrates in the gut, sweet taste receptors
(T1R2 þ T1R3), a-gustducin, and several other proteins com-
prising a full signalling machinery similar to that found in
the mouth have been identified in enteroendocrine cells of
the rodent(21) and human small intestine and colon(2,22).
Several studies have shown co-localisation of taste receptors
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with GLP-1, GIP, PYY and cholecystokinin(2,3,22). In addition,
studies in mice using knockout models for a-gustducin
(a-gust 2 /2) or T1R3 (T1R3 2 /2) have revealed impaired
glucose-stimulated incretin secretion(2). In vitro, both carbo-
hydrate sugars and the AS sucralose were capable of stimulat-
ing GLP-1 and GIP release from enteroendocrine cell lines
(GLUTag, NCI-H716); more importantly, lactisole, a sweet
receptor antagonist, blocked the secretion of GLP-1(2,4).
Based on these studies, it has been suggested that the gut
directly senses glucose or other sweet compounds by taste-
signalling elements expressed in L cells and that this leads to
GLP-1 release from these same cells(11).
Here, we have investigated in healthy human subjects
whether sweetness-matched carbohydrate sugars and AS
have equivalent effects on the release of GI satiety peptides,
glucose homeostasis and appetite feelings. The data reveal
that mainly glucose, and to a small extent fructose, stimulated
GLP-1 and PYY release and reduced ghrelin secretion; both
also affected appetite with (albeit not significantly) increased
satiety and fullness compared with water. The equisweet AS
loads did not affect GI peptide secretion with minimal effects
on appetite compared with water. These findings correspond
to human studies also reporting a lack of effect of AS on
incretin release, plasma glucose, C-peptide and gastric empty-
ing(23–25); however, the data are in contrast to the above-
mentioned in vitro studies. This may be due to the simple
fact that cell culture-based in vitro experiments do only
model human physiology, whereas in vivo, the regulatory
interface of the GI tract is much more complex and modulated
by multiple homeostatic and non-homeostatic factors. In
addition, studies in mice and rats have indicated that the
majority of incretin-expressing cells in the duodenum and
jejunum do not co-localise with a-gustducin(26,27), suggesting
that the taste receptor pathway is not the only one involved
in signal transduction and subsequent GI peptide secretion.
Other, non-taste receptor-mediated mechanisms might be
involved in the induction of GI peptide release. Several
studies have suggested that the secretion of incretins is also
dependent on actively absorbed carbohydrate sugars: in
rats, glucose-stimulated GIP secretion was markedly sup-
pressed not only by gymnemic acid (a potent blocker of
sweet taste) but also by phlorizin, which inhibits the active
transport of glucose by the Na-dependent glucose co-
transporter 1(28). In addition, in vitro studies using the enter-
oendocrine GLUTag cell line have shown that GLP-1 release
was impaired when glucose absorption was blocked with
phlorizin(29). Further studies by Ritzel et al.(30) have shown
that when the non-sweet, non-metabolisable sugar-ana-
logues, 3-O-methylglucose (absorbed via passive and active
glucose transport systems) and 2DG (absorbed only via
passive glucose transport systems) were perfused into the
rat ileum, 3-O-methylglucose induced the secretion of
GLP-1, whereas 2DG did not, suggesting that the release
of GLP-1 is independent of intracellular metabolism but
dependent on active cellular uptake.
In this regard, we performed an experiment to test whether
an intragastric load of 2DG affects GLP-1, PYY or ghrelin
secretion. The data show that 2DG does not affect peptideT
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secretion, confirming previous animal and in vitro data for
humans and extending the findings to PYY and ghrelin
secretion. 2DG is known to reduce intracellular glucose
utilisation by competitively inhibiting hexokinase activity
and glucose membrane carrier systems. The resulting intra-
cellular glucoprivation induces counter-regulatory mechan-
isms leading to hyperglycaemia(31,32). The almost linear rise
in blood glucose concentrations in the present study reflects
these metabolic effects; although blood glucose concen-
trations are high, cellular utilisation of glucose at cerebral
and peripheral glucosensitive sites did not occur. The
observed side effects (heat flushes and sweating) further
suggest sympathetic activation. In parallel, we observed a
marked increase in hunger feelings. 2DG has been demon-
strated to augment food intake and thirst in mammalian
species including rats, pigs, monkeys and humans due to
the functional hypoglycaemic state(32). Our data, therefore,
support the basic concept of decreasing blood glucose as a
metabolic correlate of hunger, namely ‘the glucostatic
theory’(33). As mentioned above, the increase in hunger was,
however, not reflected by increased plasma ghrelin concen-
trations or alterations in plasma GLP-1 or PYY.
Fructose infusions (25 g) did not affect GLP-1, PYY and
ghrelin plasma concentrations to the same extent as the equis-
weet loads of glucose (50 g); however, fructose induced
plasma levels much closer to those observed after glucose
infusions than the AS. It is arguable that the different molar
load may have affected peptide secretion differentially; how-
ever, previous human data document that GLP-1 secretion in
response to equal doses (75 g) of either fructose or glucose
is less for fructose(34). The relationship between the molecular
structure of carbohydrate sugars and their ability to stimulate
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the release of GLP-1 or GIP has been investigated in
detail(35,36). Sirinek et al.(36) demonstrated that only glucose
and, to a lesser extent, galactose (C-4 epimer), but not fructose
(C-2 keto sugar), mannose (C-2 epimer) or sorbitol (reduced
alcohol of glucose), can stimulate the release of GIP. Based
on these observations, it has been proposed that a special
sugar sensor with specific steric requirements is necessary to
directly stimulate incretin release(36).
The finding that AS have less effect on satiety, fullness and
hunger ratings compared with carbohydrate sugars confirms
the lack of post-ingestive mechanisms and supports recent
findings in rats, suggesting that the consumption of AS might
lead to increased body weight and obesity(37). However,
correlations between appetite ratings and amount of food con-
sumed are quite small, and we did not directly measure food
intake. The observed satiating effects of fructose in compari-
son with the effects of glucose, together with the rather
small effects of fructose on peptide levels, suggest that
additional mechanisms must operate to terminate a meal
and/or to determine inter-meal satiety. Initial studies by
Blundell et al.(38–40) and a few other studies have reported
energy compensation in humans when energy-containing
sugars were replaced by AS. A large number of subsequent
studies could, however, not show an effect of AS on appetite
and food intake(41–43).
Conclusions
Sweet taste detection via T1R2 þ T1R3 is suggested to be one
potential mechanism by which glucose is sensed in gut
enteroendocrine cells to trigger peptide secretion. Here, we
demonstrate that equisweet solutions of either glucose, fruc-
tose or AS have different effects on gut peptide secretion:
only glucose potently stimulates the secretion of GLP-1 and
PYY and decreases ghrelin; in contrast, fructose is much less
effective and AS have no effect. We infer from these obser-
vations that sweetness per se is not sufficient to stimulate the
secretion of these peptides in humans. Additional chemosen-
sory mechanisms directed towards the structural integrity of
the glucose molecule (as one of the major fuels for the
body) must exist including active transport systems. Finally,
potential energy-sensing mechanisms or energy thresholds
might exist for the secretion of GLP-1 and PYY, although it
is unlikely that the release is directly related to the energetic
load in a dose–response manner.
Our experimental approach was based on equisweet sol-
utions, so we cannot exclude that different molar loads and
osmolarities would have affected peptide secretion differen-
tially. Also, we cannot rule out that under certain conditions,
AS may enhance GLP-1 release when mixed with glucose, as
it has been suggested that AS might indirectly contribute to
GIP and GLP-1 release by modulating the expression of
Na-dependent glucose co-transporter 1. These considerations
are questions for future research; they are based, at least in
part, on the present findings showing that the stimulation of
gut sweet taste receptors per se is not sufficient to produce
relevant regulatory peptide responses.
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